Chris Reindel

Senior Vice President, Global Finance

Geneva Metropolitan Area

About

Global Life Sciences Business and Finance leader. Currently SVP Global Finance at Santen, a listed global Pharmaceutical company focused on Ophthalmology. Prior to this, I had been Chief Business Officer and in various senior Finance roles at Santen, including CFO for International, EMEA and North America. Prior to this I held leadership positions within two of the leading Global BioPharma companies and have experience supporting both R&D and Commercial businesses. I also have significant experience in Mergers & Acquisitions, both within Consulting and Industry. Experienced in business transformation, driving business growth and profit improvement. Specialties: Biotech/Pharma R&D and Commercial Mergers & Acquisitions

Experience

  • Santen Pharmaceutical (Full-time · 14 yrs 9 mos)
    • Senior Vice President, Global Finance
      Apr 2024 - Present · 2 yrs 4 mos

      New role as no. 2 to the Global CFO. Responsible for managing all teams globally, business and organizational transformation, operational effectiveness, driving profitable growth, Global R&D Finance, Global Procurement, M&A

    • Chief Business Officer
      Apr 2022 - Apr 2024 · 2 yrs 1 mo

      Global Officer role reporting to the CEO and member of the Executive Management Team. Responsible for commercialization of global products, portfolio strategy, enhancing the value of pipeline assets and improving business profitability across the business

    • CFO - International
      Oct 2019 - May 2022 · 2 yrs 8 mos

      Promoted into a new role as RoW CFO responsible for EMEA, US, China and APAC regions. Business transformation and corporate restructuring. Responsible for ex-Japan business performance management, Global Treasury strategy and operations, Global Tax strategy, M&A, Global R&D Finance, International FP&A

  • Director, Head of Commercial FP&A at Gilead Sciences
    Aug 2009 - Oct 2011 · 2 yrs 3 mos

    Accountable for supporting Gilead's $6bn Americas Commercial business and business partner to the head of Commercial. Disease areas include Anti-Viral, Cardiovascular, Respiratory and Liver Disease. Head of the Commercial FP&A group and responsible for short and long-term planning, pricing strategy, reimbursement, co-pay programs, impact of Health Care Reform, distributor channel strategy, product launches, JVs, ERP design and implementation

  • Genentech (4 yrs)
    • Director - Head of R&D Finance
      Mar 2007 - Aug 2009 · 2 yrs 6 mos

      Drive short and long term financial planning within the R&D business. Provide financial analysis and context to support teams going to Early and Late Stage product portfolio committees. Provide financial analysis and insight to Committee members regarding short and long term impact of decisions on the portfolio

    • Associate Director - R&D Finance
      Sep 2005 - Feb 2007 · 1 yr 6 mos

      Led a team providing accounting, planning, reporting and decision support to the molecule core teams.

  • EY (12 yrs 9 mos)
    • M&A - Senior Manager (US)
      Jan 2002 - Sep 2005 · 3 yrs 9 mos

      Led M&A transactions for corporate, private equity and VC clients, primarily in the life sciences and technology sectors. Based in San Francisco and Silicon Valley area

    • M&A - Senior Manager (UK)
      Jun 1995 - Dec 2001 · 6 yrs 7 mos

      Led buy and sell-side M&A transactions and IPOs across a number of industry sectors. Based in UK and working on global transactions

    • Mergers and Acquisitions Manager (UK)
      1993 - May 1995 · 2 yrs 5 mos

      Based in the UK and working on teams for buy and sell-side M&A transactions and IPOs across a number of industry sectors, mainly in UK and Europe

  • Audit Senior at Ernst & Young - UK
    1988 - 1992 · 4 yrs

    Audit lead on Public company audits